[{"Assets_0_Q3_USD":1024366000.0,"CommonStockSharesOutstanding_0_Q3_shares":298881884.0,"NetCashProvidedByUsedInOperatingActivities_3_Q3_USD":311129000.0,"NetIncomeLoss_1_Q3_USD":126630000.0,"NetIncomeLoss_3_Q3_USD":329981000.0,"WeightedAverageNumberOfDilutedSharesOutstanding_1_Q3_shares":312346000.0,"WeightedAverageNumberOfDilutedSharesOutstanding_3_Q3_shares":313200000.0,"WeightedAverageNumberOfSharesOutstandingBasic_1_Q3_shares":298416000.0,"WeightedAverageNumberOfSharesOutstandingBasic_3_Q3_shares":297700000.0,"EarningsPerShareBasic_1_Q3_USD":0.42,"EarningsPerShareBasic_3_Q3_USD":1.11,"EarningsPerShareDiluted_1_Q3_USD":0.41,"EarningsPerShareDiluted_3_Q3_USD":1.05,"RevenueFromContractWithCustomerExcludingAssessedTax_1_Q3_USD":225397000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_3_Q3_USD":625224000.0,"Ticker":"EXEL","CIK":"939767","name":"EXELIXIS, INC.","OfficialName":"Exelixis Inc. Common Stock","form":"10-Q","period":"20180930","fy":"2018.0","fp":"Q3","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"7287350058.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Commercial Physical & Biological Resarch","Market":"NASDAQ","SP500":"nan","filed":"20181101"}]